Overview

• The biodegradable gel combines FDA-approved PLGA with a pH-sensitive Eudragit L-100 polymer to deliver levodopa and carbidopa steadily over seven days without significant toxicity.
• Laboratory tests confirmed more than 90% of levodopa and over 81% of carbidopa released in seven days with implant degradation exceeding 80%.
• Researchers led by Professor Sanjay Garg and Deepa Nakmode have filed an Australian patent for the once-weekly injectable aimed at replacing multiple daily oral doses.
• The team is preparing ethics submissions and protocols for animal studies, with human clinical trials to follow pending regulatory approvals.
• Parkinson’s Australia has endorsed the innovation for its potential to ease dosing burdens and improve adherence, especially in elderly patients with swallowing difficulties.